Sort   by:  
 Page size 
ProteomicsO-GlcNAcylation promotes Palbociclib resistance in breast cancer by regulating MITF nuclear translocation
Cyclin-dependent kinases 4 and 6 (CDK4/6) are essential drivers of the cell cycle and are also critical for the initiation and progression of diverse malignancies. Pharmacological inhibitors targeting CDK4/6 have demonstrated significant activity against various tumor types such as breast cancer. Ho...
ORGANISM(S): Homo sapiens (Human) 
2024-05-30 | PXD042763 | Pride
O-glcnacylation Mitf Palbociclib 
ProteomicsO-GlcNAcylation promotes Palbociclib resistance in breast cancer by regulating MITF nuclear translocation
Cyclin-dependent kinases 4 and 6 (CDK4/6) are essential drivers of the cell cycle and are also critical for the initiation and progression of diverse malignancies. Pharmacological inhibitors targeting CDK4/6 have demonstrated significant activity against various tumor types such as breast cancer. Ho...
ORGANISM(S): Homo sapiens (Human) 
2024-05-30 | PXD042838 | Pride
Mitf Palbociclib O-glcnac 
UnknownMezigdomide is effective alone and in combination with menin inhibition in preclinical models of KMT2A-r and NPM1c AML.
Not available
S-EPMC11033588 | biostudies-literature
ProteomicsAnd-1 is required for NER repair and promotes skin carcinogenesis
Our project was focused on And-1 regulates NER repair and skin carcinogenesis
ORGANISM(S): Homo sapiens (Human) 
2025-08-21 | PXD052800 | Pride
And-1 Ner repair Skin carcinogenesis 
ProteomicsMezigdomide is effective alone and in combination with Menin inhibition in Acute Myeloid Leukemia
Small molecules that target the MENIN-KMT2A protein-protein interaction (Menin inhibitors) have recently entered clinical trials in lysine methyltransferase 2A (KMT2A, MLL1) rearranged (KMT2A-r) and nucleophosmin mutant (NPM1c) acute myeloid leukemia (AML) and are demonstrating encouraging results. ...
ORGANISM(S): Homo sapiens (Human) 
2024-02-15 | PXD041737 | Pride
Menin-kmt2a Menin inhibitor Acute myeloid leukemia Mezigdomide Ikaros 
ProteomicsMezigdomide is effective alone and in combination with Menin inhibition in Acute Myeloid Leukemia
Small molecules that target the MENIN-KMT2A protein-protein interaction (Menin inhibitors) have recently entered clinical trials in lysine methyltransferase 2A (KMT2A, MLL1) rearranged (KMT2A-r) and nucleophosmin mutant (NPM1c) acute myeloid leukemia (AML) and are demonstrating encouraging results. ...
ORGANISM(S): Homo sapiens (Human) 
2024-02-15 | PXD041735 | Pride
Menin-kmt2a Menin inhibitor Acute myeloid leukemia Mezigdomide Ikaros 
UnknownMEN1 mutations mediate clinical resistance to menin inhibition.
Not available
S-EPMC10157896 | biostudies-literature
UnknownPreclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemias.
Not available
S-EPMC11419783 | biostudies-literature
Sort   by:  
 Page size